Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma

Limited studies have focused on developing prognostic models with trans-omics biomarkers for early-stage lung adenocarcinoma (LUAD).We performed integrative analysis of clinical information, DNA methylation, and gene expression data using 825 early-stage LUAD patients from 5 cohorts.Ranger algorithm was used to screen prognosis-associated biomarkers, which were confirmed with a validation phase.Clinical and biomarker information was fused using an iCluster plus algorithm, which significantly distinguished patients into highand low-mortality risk groups (Pdiscovery = 0.01 and Pvalidation = 2.71×10 -3 ).Further, potential functional DNA methylation-gene expression-overall survival pathways were evaluated by causal mediation analysis.The